Daichi Sadato

バイオインフォマティシャン@都立駒込病院、ゲノム解析、#AML、#MDS

Bioinfomatician@Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Genome analysis, #AML, #MDS

[Daichi Sadato @DaichiSadato]

今後、ちょっとしたことは日本語のみのつぶやきを始めようと思う。

I think I'll start tweeting only in Japanese for small things.

[日本がん対策新聞@かんぱち編集長 @gantaisaku1105]

《治験情報》
【膵がん】話題の「ダラクソンラシブ」、膵がんの一次治療に対するPhase3試験『RASolute 303』が日本でも開始される。「ゲムシタビン＋アブラキサン」に対し、単剤治療、上乗せ治療の有用性を検証。
https://t.co/93V635R7Kf

[Matilde Boada @matilde_boada]

@MDella_Porta IPSS-M-Evo … towards a new prognostic model y MDS. The importance of longitudinal follow up… @EHA_Hematology #EHA2026

[Mostafa Faisal @MostafaFaisal14]

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study @BloodPortfolio
https://t.co/2OqncUbCxL

[Mostafa Faisal @MostafaFaisal14]

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome | Leukemia https://t.co/mMycBeEJNk

[Journal of Experimental Medicine @JExpMed]

#Myeloid diversity in tumors: shaped by genes, location, and time. Review by Maria Nogales-Pons, Mariola Munárriz-Paños, Teresa Aceña-Gonzalo, & María Casanova-Acebes @Casanova_Acebes: https://t.co/jjWBCjZ9UX

📘 Part of JEM #Cancer Collection: https://t.co/YPWs2KQyqx
#EACR2026

[Cancer Cell @Cancer_Cell]

Online Now: Pathogenesis of diffuse large B cell lymphoma proteogenotypes https://t.co/ZqArY6bzY6

[Daichi Sadato @DaichiSadato]

Key findings:
📍 Colon cancer: WH focusing on poorly differentiated adenocarcinoma (WH-por) is optimal.
📍 Rectal cancer: The standard WH approach performs better.
This approach helps identify low-risk patients, supporting personalized decisions on additional surgery. 🩺✨

[Daichi Sadato @DaichiSadato]

Our new paper is out in DEN Open! We developed a T1b-specific risk stratification framework for lymph node metastasis (LNM) in colorectal cancer using a reproducible Worst Histology (WH) approach.
🔗 Read it here: https://t.co/ULka1SKiem

[Blood Journals Portfolio @BloodPortfolio]

MDS/AML with MDR mutations display overall different mutation profiles and improved prognosis, when compared to corresponding AML subtype. Read the full article in Blood Advances: https://t.co/UA0lqk0DUC #AML #BloodAdvances

[Mostafa Faisal @MostafaFaisal14]

The impact of female-to-male allogeneic hematopoietic cell transplantation on survival outcomes varies by recipient age @ASTCT_Journal
https://t.co/ykPPR1n3bv

[Blood Journals Portfolio @BloodPortfolio]

Integrative genomic profiling improves diagnostic resolution and risk stratification of B-ALL using WHO-HAEM5 and ICC classifications. Updated classifications reveal distinct subtypes and highlight limitations that require refinement of B-ALL taxonomy. https://t.co/VZNKhhFzYC

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[GemMed（旧メディ・ウォッチ） @medwatchjp]

「造血器腫瘍の診療実態」と「がんゲノム医療提供体制」との整合性を、がん拠点病院等の指定要件見直しに向け学会等から意見聴取！

◆「造血器腫瘍の診療実態」と「がんゲノム医療提供体制」との整合性を、がん拠点病院等の指定要件見直しに向け学会等から意見聴取
https://t.co/DZfqbHmatJ

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

DDX41 may be the most common inherited AML/MDS predisposition syndrome… yet many cases are likely missed.

Think:
• older AML/MDS
• longstanding cytopenias
• normal karyotype
• subtle family history

Why it matters:
⚠️ donor selection
⚠️ family screening
⚠️ transplant decisions

Interestingly, DDX41 AML also appears highly venetoclax-sensitive with surprisingly favorable outcomes.

PSNS summary below 👇

#AML #hemetwitter
#BMT #MDS

Dr. Fun +G

[Blood Cancer Discovery @BCD_AACR]

Read this just published research article by Ulrich Steidl, et al. “Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia.” #Myeloid2026 https://t.co/rQWihjz6G0 @MontefioreNYC

[Ahmed Kotb @AhmedKo45911157]

Lower-risk MDS 📌

Anemia:
RS → luspatercept
del(5q) → lenalidomide
Others → ESA

Hypoplastic MDS → immunosuppression

Thrombocytopenia → TPO-RA

Refractory disease → HMA / consider transplant

https://t.co/c64Thejewq

[Haematologica @Haematologica]

Review series on clonal hematopoiesis: how should clinicians approach clonal hematopoiesis in practice?
This review outlines current strategies for risk assessment, monitoring, and clinical decision-making.
https://t.co/GLf7CKmA1Q

[Abdel-Wahab Lab @AbdelWahablab]

Excited to present the first pre-print from our group, an investigation the human bone marrow microenvironments in patients with myelodysplastic syndromes (MDS) and normal age-matched subjects using Xenium genotype-informed spatial transcriptomics:

https://t.co/5fS09Yl38G

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

Low-dose azacitidine maintenance after #HCT is well tolerated in pediatric high-risk myeloid malignancies with 3-year OS 91% and RFS 73%. Favorable outcomes support prospective study. Read more: https://t.co/RtM8uVZkAI

[Nicholas Hornstein @GIMedOnc]

Daraxonrasib in PDAC now published in NEJM.
We have had press releases and presentations, but now a publication.
And yes, the data still look very real. 🧬

Pancreatic cancer is a RAS disease.
90% have activating RAS mutations.
G12D, G12V, G12R dominate.
And historically we have had essentially nothing direct to do about it (G12C inhibitors exist but they are a subpopulation).

Phase 1/2
Previously treated RAS-mutant PDAC
n=168
Oral RAS(ON) multi-selective inhibitor
Phase 3 dose: 300 mg daily
• ORR 35%
• mDoR 8.2 months
• mPFS 8.5 months
• mOS 13.1 months
As context; 2L chemo w/ PDAC has ORR <10% with OS ~5-7 months and significant side effects. So yes, this is huge.

Toxicity is real too:
• Any-grade TRAE 96%
• Grade ≥3 TRAE 30%
• Rash, diarrhea, nausea, mucositis, vomiting, fatigue

This is not a “write the script and see them in a month” drug.
Up-front oncoderm involvement is going to be critical. Rash needs to be anticipated, managed early, and dose modifications need to be normalized rather than viewed as failure.

BUT this is a absolute game-changer in pancreas cancer (and other KRAS driven diseases).
Importantly, this no longer exists in a phase 1/2 vacuum.

By press release, RASolute 302 met its primary and key secondary endpoints, with PFS and OS benefit versus standard chemotherapy. Full data still matter, but the confirmatory study appears to have confirmed the signal.

Terrible disease.
Great signal.
Real (but manageable) toxicity.
Practice-changing.

https://t.co/lJ8IbQydlP

@OncoAlert @TheGutOncLab @Onco_Nexus